Alopecia Areata Market Outlook 2031:
The global alopecia areata market size was valued at USD 2.96 Billion in 2022 and is projected to reach USD 5.04 Billion by 2031, expanding at a CAGR of 10% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising prevalence of hair loss.
Alopecia areata is a type of alopecia, which refers to an autoimmune disorder, which causes hair fall or hair loss in oval or round shape and in patches. Alopecia areata is unpredictable, where hair can regrow after some bald patches. Conversely, sometimes hair do not grow back and bald patches can expand. Rash, redness, and scarring can appear on the bare spots. Itching, burning, or tingling can be felt in these patches as well.
Alopecia areata primarily affects hair; however, in some cases, it can affect nails as well. Ridges and pits can occur on nails for some people affected by severe hair loss. Anyone can develop alopecia areata; however, individuals related to a person suffering from the disease or other autoimmune disorders such as lupus, diabetes, and thyroid have high chances of contracting alopecia areata.
Alopecia Areata Market Trends, Drivers, Restraints, and Opportunities
- Growing investments in healthcare infrastructure boosts the market.
- Increasing prevalence of alopecia areata across the globe is expected to drive the market during the forecast period.
- Rising awareness regarding alopecia areata is estimated to fuel the market in the coming years.
- Rising cases of autoimmune diseases and fast changing lifestyle spurs the market.
- High cost of alopecia areata treatment is expected to hamper the growth of the market during the forecast period.
- Lack of awareness regarding the diseases in developing countries hinders the growth of the market.
- Increasing number of research and development activities regarding alopecia areata offer growth opportunities to the key market players.
Scope of the Alopecia Areata Report
The report on the global alopecia areata market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Alopecia Areata Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2021
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Types (Alopecia Areata (Patchy), Persistent Patchy Alopecia Areata, Alopecia Areata Totalis, Diffuse Alopecia Areata, Alopecia Areata Universalis, Ophiasis Alopecia Areata, and Others), Diagnosis (Skin Biopsy, Trichoscopy, Blood Test, and Others), Treatments (Corticosteroid Drugs, Steroids, Anti-Inflammatory Drugs, Vasodilator, Immunosuppressive Drugs, UV Light Therapy, and Others), Routes of Administration (Topical, Oral, Parenteral, and Others), Distributions Channels (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others), and End-users (Specialty Clinics, Hospitals, Homecare, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Pfizer, Inc.; Bayer AG; Cipla, Inc.; Teva Pharmaceuticals Industries Ltd.; Aclaris Therapeutics, Inc.; Sanofi; Mylan N.V.; Novartis AG; GSK Group of Companies; AbbVie, Inc.; Lupin; Merck KGaA; Sun Pharmaceuticals Industries, Ltd.; AstraZeneca; Eli Lilly and Company; Perrigo Company plc; and Others
|
Alopecia Areata Market Segment Insights
Alopecia areata (patchy) segment drives the market
Based on Types, the market is divided into alopecia areata (patchy), persistent patchy alopecia areata, alopecia areata totalis, diffuse alopecia areata, alopecia areata universalis, ophiasis alopecia areata, and others.
The alopecia areata (patchy) segment is expected to boost the market during the forecast period, due to increasing prevalence of individuals suffering from autoimmune disorders. Rapidly changing lifestyle and increasing stress among individuals across the globe are key factors, which aid in the expansion of the market.
Blood test segment boosts the market
In terms of diagnosis, the market is segregated into skin biopsy, trichoscopy, blood test, and others. The blood test segment is projected to drive the market during the forecast period, as doctors can check for medical conditions such as thyroid, immune system problems, hormone, and others that can cause hair loss.
Corticosteroid drugs segment holds a key market share
On the basis of treatments, the market is segmented into corticosteroid drugs, steroids, anti-Inflammatory drugs, vasodilator, immunosuppressive drugs, UV light therapy, and others.
The corticosteroid drugs segment is estimates to fuel the market during the forecast period, due to their lipid-regulating and anti-inflammatory properties. Increasing usage of corticosteroid drugs in clinical trials aids in the expansion of the segment.
Topical segment registers a high CAGR
In terms of routes of administrations, the market is divided into topical, oral, parenteral, and others. The topical segment is estimated to hold a key market share during the forecast period, owing to increasing demand for topical alopecia areata treatments.
The topical treatment solutions such as medicated hair serum, medicated shampoos, gel, and topical ointment are easily available, easy to use, and non-invasive. Increasing research and development activities in topical treatment solutions aid in the expansion of the segment.
Hospital pharmacy segment spurs the market
Based on distribution channels, the market is segregated into hospital pharmacy, online pharmacy, retail pharmacy, and others. The hospital pharmacy segment is estimated to fuel the market during the forecast period, due to easy availability of alopecia areata treatment prescription drugs in hospital pharmacies.
The online pharmacy segment is anticipated to expand in the coming years, owing to growing penetration of internet, increasing usage of smart devices, rising number of online pharmacies, and increasing benefits of purchasing from online pharmacies such as wide range of products, product comparison, door-step delivery, easy payment methods, and others.
Specialty clinic expands rapidly
On the basis of end-users, the market is distributed into specialty clinics, hospitals, homecare, and others. The specialty clinics segment is expected to drive the market during the forecast period, due to growing number of trichologists and dermatologist across the globe.
Increasing awareness regarding alopecia areata and benefits of hair treatment is drawing individuals across the globe to specialty clinics. These factors aid in the expansion of the segment.
North America dominates the market
In terms of regions, the market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market in North America is estimated to hold a significant market share during the forecast period, due to increasing research and development activities regarding alopecia areata in the region.
Increasing cases of hair loss, growing expenditure in healthcare sector, rising early phase diagnosis of the disease, and favorable government policies for hair care companies drive the market in the region. The market in Asia pacific is anticipated to register a high CAGR during the forecast period, owing to increasing cases of alopecia areata among young population, rapidly changing lifestyle, and rising awareness regarding alopecia areata in the region.
Segments
The global alopecia areata market has been segmented on the basis of
Types
- Alopecia Areata (Patchy)
- Persistent Patchy Alopecia Areata
- Alopecia Areata Totalis
- Diffuse Alopecia Areata Areata
- Alopecia Areata Universalis
- Ophiasis Alopecia Areata
- Others
Diagnosis
- Skin Biopsy
- Trichoscopy
- Blood Test
- Others
Treatments
- Steroids
- Anti-Inflammatory Drugs
- Vasodilator
- Immunosuppressive Drugs
- UV Light Therapy
- Others
Routes of Administration
- Topical
- Oral
- Parenteral
- Others
Distributions Channels
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
End-users
- Specialty Clinics
- Hospitals
- Homecare
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Pfizer, Inc.
- Bayer AG
- Cipla, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Aclaris Therapeutics, Inc.
- Sanofi
- Mylan N.V.
- Novartis AG
- GSK Group of Companies
- AbbVie, Inc.
- Lupin
- Merck KGaA
- Sun Pharmaceuticals Industries, Ltd.
- AstraZeneca
- Eli Lilly and Company
- Perrigo Company plc
- Others
Competitive Landscape
The global alopecia areata market is competitive with the presence of key players such as Pfizer, Inc.; Bayer AG; Cipla, Inc.; Teva Pharmaceuticals Industries Ltd.; Aclaris Therapeutics, Inc.; Sanofi; Mylan N.V.; Novartis AG; GSK Group of Companies; AbbVie, Inc.; Lupin; Merck KGaA; Sun Pharmaceuticals Industries, Ltd.; AstraZeneca; Eli Lilly and Company; Perrigo Company plc; and others, who use strategies such as acquisitions, mergers, collaborations, product launches, and partnerships to strengthen their hold on the market.
For example, in March 2020, Eli Lily and Company collaborated with Incyte Corporation to formulate a treatment for alopecia areata, which received a breakthrough therapy designation from the US Food and Drug Administration.
In July 2019, Aclaris Therapeutics, Inc. announced a positive result for ATI-501, which is an oral drug for treating alopecia areata.